Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
18.07. | OKYO Pharma Ltd - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings | ||
OKYO PHARMA Aktie jetzt für 0€ handeln | |||||
17.07. | OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain | 297 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 17, 2025), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic... ► Artikel lesen | |
17.07. | OKYO Pharma stock maintains Buy rating at H.C. Wainwright on positive trial data | 2 | Investing.com | ||
16.07. | OKYO Pharma Stock Rises 8% On Positive Phase 2 Trial Results For Neuropathic Corneal Pain Therapy | 3 | RTTNews | ||
16.07. | OKYO Pharma reports results from Urcosimod trial | 2 | Seeking Alpha | ||
16.07. | OKYO Pharma meldet positive Top-Line-Ergebnisse aus Phase-2-Studie mit Urcosimod/n | - | Investing.com Deutsch | ||
16.07. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
16.07. | Positive Studiendaten zu Augenschmerzmittel beflügeln OKYO-Pharma-Aktie | 1 | Investing.com Deutsch | ||
16.07. | OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain | 164 | GlobeNewswire (Europe) | After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual Analogue Scale (VAS), demonstrating... ► Artikel lesen | |
16.07. | OKYO Pharma stock surges after positive Phase 2 results for eye pain drug | 2 | Investing.com | ||
11.06. | Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited | 337 | ACCESS Newswire | Raising Price Target Due to Fundamental Drivers BALTIMORE, MD / ACCESS Newswire / June 11, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap... ► Artikel lesen | |
11.06. | OKYO Pharma to Present at the Bio International Convention | 262 | GlobeNewswire (Europe) | LONDON and NEW YORK, June 11, 2025), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA... ► Artikel lesen | |
11.06. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
19.05. | OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit | 268 | GlobeNewswire (Europe) | LONDON and NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic... ► Artikel lesen | |
19.05. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
06.05. | Okyo Pharma - Targeting underserved corneal diseases | 190 | Edison Investment Research | OKYO Pharma is advancing lead candidate urcosimod (previously OK-101) for neuropathic corneal pain (NCP), an area of unmet need with no approved treatment, as well as for inflammatory dry eye disease... ► Artikel lesen | |
01.05. | OKYO Pharma LTD: FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain | 343 | GlobeNewswire (Europe) | LONDON and NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to... ► Artikel lesen | |
30.04. | OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain | 340 | GlobeNewswire (Europe) | Urcosimod phase 2 trial treating Neuropathic Corneal Pain ("NCP") patients was initiated in October 2024 and designed as a double-masked, randomized, 12-week placebo-controlled trial.OKYO Pharma plans... ► Artikel lesen | |
30.04. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
31.03. | OKYO Pharma reports long-term benefits of its neuropathic corneal pain treatment | 5 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 92,25 | -0,54 % | BioNTech-Aktie vor nächster Rallye? Auf diese 2 Dinge warten jetzt alle Anleger | Nach der Corona-Zeit wartet die BioNTech-Aktie weiter auf den nächsten großen Durchbruch. Eine neue Rallye an der Börse könnte aber nicht mehr lange auf sich warten lassen. Das Corona-Momentum, dass... ► Artikel lesen | |
MEDIGENE | 0,103 | -16,33 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
QIAGEN | 42,770 | -2,35 % | DZ BANK stuft QIAGEN NV auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat den fairen Wert für Qiagen von 47 auf 52 Euro angehoben und die Einstufung auf "Kaufen" belassen. Qiagen sei zurück auf dem Wachstumspfad, die operative... ► Artikel lesen | |
CUREVAC | 4,690 | +0,51 % | CureVac mit UNGLAUBLICHER Prognose: Könnte die Aktie jetzt komplett drehen - Experten empfehlen SOFORT zu handeln! | ||
AMGEN | 256,70 | +0,04 % | Soligenix Drug Matches FDA-Approved Amgen Therapy In Rare Disease Trial | ||
NOVAVAX | 5,659 | -0,28 % | Novavax poised to end in red for seventh straight session | ||
CRISPR THERAPEUTICS | 49,200 | +1,23 % | The 3 Things That Matter for CRISPR Therapeutics Now | ||
REGENERON PHARMACEUTICALS | 473,30 | -2,11 % | Regeneron lymphoma therapy odronextamab rejected by FDA again | ||
VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, INC. - 10-K/A, Annual Report | ||
INOVIO PHARMACEUTICALS | 1,230 | -0,81 % | INOVIO Pharma Announces Proposed Public Offering | WASHINGTON (dpa-AFX) - INOVIO Pharmaceuticals Inc. (INO) announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof)... ► Artikel lesen | |
SANGAMO THERAPEUTICS | 0,490 | +1,16 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
INFLARX | 0,766 | +2,41 % | InflaRx N.V.: InflaRx to Report Second Quarter 2025 Results on August 7, 2025 | ||
VIKING THERAPEUTICS | 28,200 | -0,18 % | Is Viking Therapeutics the Next Big Biotech Bet? | ||
INTELLIA THERAPEUTICS | 9,820 | -1,09 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
BIO-GATE | 0,945 | -2,58 % | Bio-Gate mit Verlust, Aktie stürzt ab | Bio-Gate hat die endgültigen Zahlen für 2024 vorgelegt. An der Börse kommen die Zahlen der Bilanz schlecht an: Die Bio-Gate Aktie notiert aktuell bei 0,82 Euro mit 20,39 Prozent im Minus. Das Unternehmen... ► Artikel lesen |